002755 奥赛康
已收盘 11-29 15:00:00
资讯
新帖
简况
奥赛康(002755)11月22日主力资金净卖出582.49万元
证券之星 · 11-22
奥赛康(002755)11月22日主力资金净卖出582.49万元
11月20日奥赛康涨5.16%,创金合信医疗保健股票A基金重仓该股
证券之星 · 11-20
11月20日奥赛康涨5.16%,创金合信医疗保健股票A基金重仓该股
奥赛康(002755)11月20日主力资金净买入799.11万元
证券之星 · 11-20
奥赛康(002755)11月20日主力资金净买入799.11万元
华福证券:给予奥赛康买入评级
证券之星 · 11-15
华福证券:给予奥赛康买入评级
奥赛康(002755)11月15日主力资金净买入2251.73万元
证券之星 · 11-15
奥赛康(002755)11月15日主力资金净买入2251.73万元
奥赛康(002755)11月8日主力资金净卖出477.12万元
证券之星 · 11-08
奥赛康(002755)11月8日主力资金净卖出477.12万元
奥赛康(002755)10月10日股东户数1.8万户,较上期增加2.22%
证券之星 · 11-05
奥赛康(002755)10月10日股东户数1.8万户,较上期增加2.22%
奥赛康(002755)11月4日主力资金净卖出214.76万元
证券之星 · 11-04
奥赛康(002755)11月4日主力资金净卖出214.76万元
奥赛康(002755)2024年三季报简析:营收净利润同比双双增长,盈利能力上升
证券之星 · 11-01
奥赛康(002755)2024年三季报简析:营收净利润同比双双增长,盈利能力上升
奥赛康(002755)9月30日股东户数1.76万户,较上期增加4.94%
证券之星 · 10-31
奥赛康(002755)9月30日股东户数1.76万户,较上期增加4.94%
图解奥赛康三季报:第三季度单季净利润同比增296.25%
证券之星 · 10-31
图解奥赛康三季报:第三季度单季净利润同比增296.25%
奥赛康最新公告:子公司马来酸奈拉替尼片获得药品注册证书
证券之星 · 10-29
奥赛康最新公告:子公司马来酸奈拉替尼片获得药品注册证书
奥赛康(002755)10月22日主力资金净卖出2041.07万元
证券之星 · 10-22
奥赛康(002755)10月22日主力资金净卖出2041.07万元
奥赛康(002755)10月17日主力资金净卖出709.07万元
证券之星 · 10-17
奥赛康(002755)10月17日主力资金净卖出709.07万元
奥赛康(002755)9月30日股东户数1.76万户,较上期增加4.46%
证券之星 · 10-14
奥赛康(002755)9月30日股东户数1.76万户,较上期增加4.46%
港股异动 | 信达生物(01801)涨超3% 近日与奥赛康药业签订合作协议 多条研发管线即将进入产品收获期
智通财经 · 10-10
港股异动 | 信达生物(01801)涨超3% 近日与奥赛康药业签订合作协议 多条研发管线即将进入产品收获期
港股异动 | 信达生物(01801)盘中再跌10% 与奥赛康药业达成战略合作 创始人近期减持超1.5亿港元股票
智通财经 · 10-08
港股异动 | 信达生物(01801)盘中再跌10% 与奥赛康药业达成战略合作 创始人近期减持超1.5亿港元股票
信达生物(01801.HK)与奥赛康药业就肺癌靶向药奥壹新达成战略合作
阿斯达克财经 · 10-08
信达生物(01801.HK)与奥赛康药业就肺癌靶向药奥壹新达成战略合作
9月30日奥赛康涨10.00%,华富健康文娱灵活配置混合A基金重仓该股
证券之星 · 09-30
9月30日奥赛康涨10.00%,华富健康文娱灵活配置混合A基金重仓该股
异动快报:奥赛康(002755)9月30日14点0分触及涨停板
证券之星 · 09-30
异动快报:奥赛康(002755)9月30日14点0分触及涨停板
公司概况
公司名称:
北京奥赛康药业股份有限公司
所属行业:
医药制造业
上市日期:
2015-05-15
主营业务:
北京奥赛康药业股份有限公司主营业务是原料药及制剂的研发、生产、销售。主要产品为奥西康、奥丽瑞、奥罗沙、奥胜明、奥一明、奥维加、奥加明、潘美路、奥诺先、奥先达、奥锐安、奥维亚、奥哌柏、奥维丽、奥地西、奥名润、奥天成、奥达路、欧丽、奥替加、爱宣奥、奥佳泽、奥伏立、奥新泽、奥心怡、奥贝怡、奥法罗、奥立来、奥康宁。奥赛康药业先后获得南京市市长质量奖、江苏省质量奖、全球卓越绩效奖世界级和中国质量奖提名奖,并获评江苏省质量信用AAA级企业、中国化学制药质量信用AAA级企业、中国医药质量管理奖、中国化学制药行业创新型优秀企业品牌、全国医药行业药品质量诚信建设示范企业、全国医药行业质量管理小组活动优秀企业等。
发行价格:
7.49
{"stockData":{"symbol":"002755","market":"SZ","secType":"STK","nameCN":"奥赛康","latestPrice":14.14,"timestamp":1732863795000,"preClose":14.1,"halted":0,"volume":6247404,"delay":0,"floatShares":927999999,"shares":927999999,"eps":0.1758,"marketStatus":"已收盘","marketStatusCode":5,"change":0.04,"latestTime":"11-29 15:00:00","open":14.05,"high":14.6,"low":13.74,"amount":88661000,"amplitude":0.061,"askPrice":14.16,"askSize":5,"bidPrice":14.14,"bidSize":33,"shortable":0,"etf":0,"ttmEps":0.1758,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1733103000000},"adr":0,"adjPreClose":14.1,"symbolType":"stock","openAndCloseTimeList":[[1732843800000,1732851000000],[1732856400000,1732863600000]],"highLimit":15.51,"lowLimit":12.69,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":928160351,"pbRate":4.38,"roa":"--","roe":"4.31%","epsLYR":-0.16,"committee":-0.494475,"marketValue":13124000000,"floatMarketCap":13124000000,"peRate":80.432311,"changeRate":0.0028,"turnoverRate":0.0067,"status":0,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2024-12-02。"},"requestUrl":"/m/hq/s/002755/wiki","defaultTab":"wiki","newsList":[{"id":"2485282498","title":"奥赛康(002755)11月22日主力资金净卖出582.49万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2485282498","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485282498?lang=zh_cn&edition=full","pubTime":"2024-11-22 15:31","pubTimestamp":1732260671,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年11月22日收盘,奥赛康报收于12.69元,下跌7.44%,换手率0.72%,成交量6.68万手,成交额8729.21万元。11月22日的资金流向数据方面,主力资金净流出582.49万元,占总成交额6.67%,游资资金净流出85.77万元,占总成交额0.98%,散户资金净流入668.25万元,占总成交额7.66%。奥赛康主营业务:聚焦于消化、抗肿瘤、抗感染、慢性病等四大主要治疗领域的产品研发、生产、销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112200020107.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002755","BK0239","BK0028"],"gpt_icon":0},{"id":"2484165410","title":"11月20日奥赛康涨5.16%,创金合信医疗保健股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484165410","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484165410?lang=zh_cn&edition=full","pubTime":"2024-11-20 16:11","pubTimestamp":1732090274,"startTime":"0","endTime":"0","summary":"证券之星消息,11月20日奥赛康涨5.16%,收盘报13.65元,换手率1.09%,成交量10.12万手,成交额1.37亿元。根据2024基金Q3季报公募基金重仓股数据,重仓该股的公募基金共12家,其中持有数量最多的公募基金为创金合信医疗保健股票A。创金合信医疗保健股票A目前规模为1.72亿元,最新净值1.5804,较上一交易日上涨0.91%,近一年下跌20.59%。创金合信医疗保健股票A的前十大重仓股如下:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112000026749.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002755"],"gpt_icon":0},{"id":"2484494157","title":"奥赛康(002755)11月20日主力资金净买入799.11万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484494157","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484494157?lang=zh_cn&edition=full","pubTime":"2024-11-20 15:25","pubTimestamp":1732087558,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年11月20日收盘,奥赛康报收于13.65元,上涨5.16%,换手率1.09%,成交量10.12万手,成交额1.37亿元。11月20日的资金流向数据方面,主力资金净流入799.11万元,占总成交额5.83%,游资资金净流出1092.46万元,占总成交额7.98%,散户资金净流入293.35万元,占总成交额2.14%。奥赛康主营业务:聚焦于消化、抗肿瘤、抗感染、慢性病等四大主要治疗领域的产品研发、生产、销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112000020886.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002755","BK0028"],"gpt_icon":0},{"id":"2483716213","title":"华福证券:给予奥赛康买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2483716213","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483716213?lang=zh_cn&edition=full","pubTime":"2024-11-15 21:56","pubTimestamp":1731678997,"startTime":"0","endTime":"0","summary":"华福证券有限责任公司陈铁林近期对奥赛康进行研究并发布了研究报告《集采出清,轻装上阵,创新转型成果已现》,本报告对奥赛康给出买入评级,当前股价为13.45元。目前首个CLDN18.2靶向疗法已获美国FDA批准上市。我们预计公司2024-2026收入分别为16.7/19/23.4亿,与可比公司估值相比,公司PS低于平均水平,首次覆盖,给予“买入”评级。最新盈利预测明细如下:该股最近90天内共有8家机构给出评级,买入评级6家,增持评级2家;过去90天内机构目标均价为17.19。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111500045172.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","002755"],"gpt_icon":0},{"id":"2483094314","title":"奥赛康(002755)11月15日主力资金净买入2251.73万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483094314","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483094314?lang=zh_cn&edition=full","pubTime":"2024-11-15 15:22","pubTimestamp":1731655326,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年11月15日收盘,奥赛康报收于13.45元,上涨5.41%,换手率1.06%,成交量9.8万手,成交额1.29亿元。奥赛康主营业务:聚焦于消化、抗肿瘤、抗感染、慢性病等四大主要治疗领域的产品研发、生产、销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111500019173.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002755","BK0028"],"gpt_icon":0},{"id":"2481145667","title":"奥赛康(002755)11月8日主力资金净卖出477.12万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481145667","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481145667?lang=zh_cn&edition=full","pubTime":"2024-11-08 15:28","pubTimestamp":1731050929,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年11月8日收盘,奥赛康报收于13.12元,下跌2.81%,换手率1.08%,成交量10.05万手,成交额1.32亿元。11月8日的资金流向数据方面,主力资金净流出477.12万元,占总成交额3.61%,游资资金净流出33.85万元,占总成交额0.26%,散户资金净流入510.97万元,占总成交额3.87%。奥赛康主营业务:聚焦于消化、抗肿瘤、抗感染、慢性病等四大主要治疗领域的产品研发、生产、销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110800020019.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002755"],"gpt_icon":0},{"id":"2481521898","title":"奥赛康(002755)10月10日股东户数1.8万户,较上期增加2.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481521898","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481521898?lang=zh_cn&edition=full","pubTime":"2024-11-05 17:01","pubTimestamp":1730797299,"startTime":"0","endTime":"0","summary":"证券之星消息,近日奥赛康披露,截至2024年10月10日公司股东户数为1.8万户,较9月30日增加391.0户,增幅为2.22%。在化学制药行业个股中,奥赛康股东户数低于行业平均水平,截至10月10日,化学制药行业平均股东户数为3.1万户。从股价来看,2024年9月30日至2024年10月10日,奥赛康区间涨幅为5.05%,在此期间股东户数增加391.0户,增幅为2.22%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110500028331.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002755"],"gpt_icon":0},{"id":"2480327845","title":"奥赛康(002755)11月4日主力资金净卖出214.76万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2480327845","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480327845?lang=zh_cn&edition=full","pubTime":"2024-11-04 15:27","pubTimestamp":1730705242,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年11月4日收盘,奥赛康报收于13.12元,下跌0.98%,换手率0.58%,成交量5.41万手,成交额7106.67万元。11月4日的资金流向数据方面,主力资金净流出214.76万元,占总成交额3.02%,游资资金净流出159.66万元,占总成交额2.25%,散户资金净流入374.42万元,占总成交额5.27%。奥赛康主营业务:聚焦于消化、抗肿瘤、抗感染、慢性病等四大主要治疗领域的产品研发、生产、销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110400013947.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002755","BK0239","BK0028"],"gpt_icon":0},{"id":"2480099273","title":"奥赛康(002755)2024年三季报简析:营收净利润同比双双增长,盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2480099273","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480099273?lang=zh_cn&edition=full","pubTime":"2024-11-01 06:46","pubTimestamp":1730414772,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期奥赛康发布2024年三季报。截至本报告期末,公司营业总收入13.84亿元,同比上升23.64%,归母净利润1.27亿元,同比上升168.79%。按单季度数据看,第三季度营业总收入4.62亿元,同比上升13.23%,第三季度归母净利润5142.32万元,同比上升296.25%。本报告期奥赛康盈利能力上升,毛利率同比增幅0.17%,净利率同比增幅140.33%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110100007546.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002755"],"gpt_icon":0},{"id":"2479726377","title":"奥赛康(002755)9月30日股东户数1.76万户,较上期增加4.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479726377","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479726377?lang=zh_cn&edition=full","pubTime":"2024-10-31 17:21","pubTimestamp":1730366512,"startTime":"0","endTime":"0","summary":"证券之星消息,近日奥赛康披露,截至2024年9月30日公司股东户数为1.76万户,较9月20日增加830.0户,增幅为4.94%。在化学制药行业个股中,奥赛康股东户数低于行业平均水平,截至9月30日,化学制药行业平均股东户数为3.1万户。从股价来看,2024年9月20日至2024年9月30日,奥赛康区间涨幅为16.47%,在此期间股东户数增加830.0户,增幅为4.94%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100034755.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","002755"],"gpt_icon":0},{"id":"2479758342","title":"图解奥赛康三季报:第三季度单季净利润同比增296.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479758342","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479758342?lang=zh_cn&edition=full","pubTime":"2024-10-31 01:50","pubTimestamp":1730310650,"startTime":"0","endTime":"0","summary":"证券之星消息,奥赛康2024年三季报显示,公司主营收入13.84亿元,同比上升23.64%;归母净利润1.27亿元,同比上升168.79%;扣非净利润1.02亿元,同比上升145.61%;其中2024年第三季度,公司单季度主营收入4.62亿元,同比上升13.23%;单季度归母净利润5142.32万元,同比上升296.25%;单季度扣非净利润4700.61万元,同比上升216.37%;负债率20.97%,投资收益974.49万元,财务费用-1206.04万元,毛利率81.83%。财报数据概要请见下图:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100002890.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002755"],"gpt_icon":0},{"id":"2479755414","title":"奥赛康最新公告:子公司马来酸奈拉替尼片获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2479755414","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479755414?lang=zh_cn&edition=full","pubTime":"2024-10-29 17:40","pubTimestamp":1730194821,"startTime":"0","endTime":"0","summary":"奥赛康公告称,其全资子公司江苏奥赛康药业有限公司近日收到国家药品监督管理局核准签发的马来酸奈拉替尼片《药品注册证书》。该药品适用于人类表皮生长因子受体2(HER2)阳性的早期乳腺癌成年患者的强化辅助治疗。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900033631.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002755","BK0239"],"gpt_icon":0},{"id":"2477058598","title":"奥赛康(002755)10月22日主力资金净卖出2041.07万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2477058598","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477058598?lang=zh_cn&edition=full","pubTime":"2024-10-22 15:25","pubTimestamp":1729581947,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年10月22日收盘,奥赛康报收于14.22元,下跌3.46%,换手率1.16%,成交量10.79万手,成交额1.56亿元。奥赛康主营业务:聚焦于消化、抗肿瘤、抗感染、慢性病等四大主要治疗领域的产品研发、生产、销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102200018337.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002755","BK0239","BK0028"],"gpt_icon":0},{"id":"2476160240","title":"奥赛康(002755)10月17日主力资金净卖出709.07万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2476160240","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476160240?lang=zh_cn&edition=full","pubTime":"2024-10-17 15:19","pubTimestamp":1729149599,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年10月17日收盘,奥赛康报收于13.68元,上涨3.48%,换手率1.31%,成交量12.12万手,成交额1.66亿元。10月17日的资金流向数据方面,主力资金净流出709.07万元,占总成交额4.27%,游资资金净流入303.72万元,占总成交额1.83%,散户资金净流入405.35万元,占总成交额2.44%。奥赛康主营业务:聚焦于消化、抗肿瘤、抗感染、慢性病等四大主要治疗领域的产品研发、生产、销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101700017687.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002755","BK0239"],"gpt_icon":0},{"id":"2475935851","title":"奥赛康(002755)9月30日股东户数1.76万户,较上期增加4.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2475935851","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475935851?lang=zh_cn&edition=full","pubTime":"2024-10-14 17:03","pubTimestamp":1728896626,"startTime":"0","endTime":"0","summary":"证券之星消息,近日奥赛康披露,截至2024年9月30日公司股东户数为1.76万户,较8月20日增加753.0户,增幅为4.46%。在化学制药行业个股中,奥赛康股东户数低于行业平均水平,截至9月30日,化学制药行业平均股东户数为3.2万户。从股价来看,2024年8月20日至2024年9月30日,奥赛康区间涨幅为5.88%,在此期间股东户数增加753.0户,增幅为4.46%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101400022512.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","002755"],"gpt_icon":0},{"id":"2474327417","title":"港股异动 | 信达生物(01801)涨超3% 近日与奥赛康药业签订合作协议 多条研发管线即将进入产品收获期","url":"https://stock-news.laohu8.com/highlight/detail?id=2474327417","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474327417?lang=zh_cn&edition=full","pubTime":"2024-10-10 10:17","pubTimestamp":1728526637,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,信达生物涨超3%,截至发稿,涨3.69%,报49.1港元,成交额2.69亿港元。消息面上,近日,信达生物与奥赛康药业签订合作协议,双方将就第三代表皮生长因子受体酪氨酸激酶抑制剂靶向药物“利厄替尼片”达成独家商业化合作。据悉,国家药监局目前正在审评审批利厄替尼片的两项适应症新药上市申请。天风证券指出,2024H1信达生物总收入为39.5亿元,同比增长46.3%;产品收入38.1亿元,同比增长55.1%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1192151.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01801","002755","LU2328871848.SGD","LU2488822045.USD","BK0239","BK1583","BK1589","BK0028","BK1161","LU1969619763.USD"],"gpt_icon":0},{"id":"2473224418","title":"港股异动 | 信达生物(01801)盘中再跌10% 与奥赛康药业达成战略合作 创始人近期减持超1.5亿港元股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2473224418","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473224418?lang=zh_cn&edition=full","pubTime":"2024-10-08 14:50","pubTimestamp":1728370228,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,信达生物盘中再跌10%,截至发稿,跌4.92%,报47.35港元,成交额16.27亿港元。值得注意的是,据香港联交所披露易公布的数据,创始人、执行董事、董事会主席兼首席执行官俞德超在9月30日和10月2日合计减持信达生物325万股,总金额约1.52亿港元。减持后,俞德超所持股份占比由7.90%降至7.70%,持股数降为约1.2597亿股。此外,9月11日,摩根大通减持信达生物1553.61万股普通股股份,价值约6.69亿港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1190866.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK0028","BK1589","002755","BK1161","LU2488822045.USD","LU1969619763.USD","01801","LU2328871848.SGD","BK0239"],"gpt_icon":0},{"id":"2473464387","title":"信达生物(01801.HK)与奥赛康药业就肺癌靶向药奥壹新达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2473464387","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473464387?lang=zh_cn&edition=full","pubTime":"2024-10-08 10:52","pubTimestamp":1728355920,"startTime":"0","endTime":"0","summary":"信达生物与奥赛康药业近日签订合作协议,双方将就第三代表皮生长因子受体酪氨酸激酶抑制剂靶向药物“利厄替尼片”达成独家商业化合作。信达生物集团创始人、董事长兼首席执行官俞德超表示,与奥赛康在奥壹新的合作有望为广大的EGFR突变肺癌患者提供一个创新靶向药物,同时将进一步提升信达生物在肿瘤治疗领域的领先地位。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190319114710011_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190319114710011_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1386644/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0239","BK1161","LU2488822045.USD","BK0028","002755","LU2328871848.SGD","01801","BK1583","BK1589","LU1969619763.USD"],"gpt_icon":0},{"id":"2471778968","title":"9月30日奥赛康涨10.00%,华富健康文娱灵活配置混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2471778968","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471778968?lang=zh_cn&edition=full","pubTime":"2024-09-30 18:16","pubTimestamp":1727691401,"startTime":"0","endTime":"0","summary":"证券之星消息,9月30日奥赛康涨10.00%创60日新高,收盘报11.88元,换手率1.11%,成交量10.34万手,成交额1.19亿元。根据2024基金半年报公募基金重仓股数据,重仓该股的公募基金共3家,其中持有数量最多的公募基金为华富健康文娱灵活配置混合A。华富健康文娱灵活配置混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024093000032359.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002755"],"gpt_icon":0},{"id":"2471782850","title":"异动快报:奥赛康(002755)9月30日14点0分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2471782850","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471782850?lang=zh_cn&edition=full","pubTime":"2024-09-30 14:06","pubTimestamp":1727676374,"startTime":"0","endTime":"0","summary":"证券之星9月30日盘中消息,14点0分奥赛康触及涨停板。目前价格11.88,上涨10.0%。该股为创新药,医药,幽门螺杆菌概念概念热股,当日创新药概念上涨11.02%,医药概念上涨10.93%,幽门螺杆菌概念概念上涨10.21%。近5日资金流向一览见下表:奥赛康主要指标及行业内排名如下:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024093000020151.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002755","BK0028"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2015-05-15","address":"北京市丰台区南四环西路188号七区28号楼","stockEarnings":[{"period":"1week","weight":0.1143},{"period":"1month","weight":0.064},{"period":"3month","weight":0.324},{"period":"6month","weight":0.3416},{"period":"1year","weight":0.3876},{"period":"ytd","weight":0.3068}],"companyName":"北京奥赛康药业股份有限公司","boardCode":"AI0027","perCapita":"51523股","boardName":"医药制造业","registeredCapital":"92816万元","compareEarnings":[{"period":"1week","weight":0.0181},{"period":"1month","weight":0.0184},{"period":"3month","weight":0.1704},{"period":"6month","weight":0.0776},{"period":"1year","weight":0.098},{"period":"ytd","weight":0.1182}],"survey":" 北京奥赛康药业股份有限公司主营业务是原料药及制剂的研发、生产、销售。主要产品为奥西康、奥丽瑞、奥罗沙、奥胜明、奥一明、奥维加、奥加明、潘美路、奥诺先、奥先达、奥锐安、奥维亚、奥哌柏、奥维丽、奥地西、奥名润、奥天成、奥达路、欧丽、奥替加、爱宣奥、奥佳泽、奥伏立、奥新泽、奥心怡、奥贝怡、奥法罗、奥立来、奥康宁。奥赛康药业先后获得南京市市长质量奖、江苏省质量奖、全球卓越绩效奖世界级和中国质量奖提名奖,并获评江苏省质量信用AAA级企业、中国化学制药质量信用AAA级企业、中国医药质量管理奖、中国化学制药行业创新型优秀企业品牌、全国医药行业药品质量诚信建设示范企业、全国医药行业质量管理小组活动优秀企业等。","serverTime":1732957942451,"listedPrice":7.49,"stockholders":"18014人(较上一季度增加2.22%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"奥赛康(002755)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供奥赛康(002755)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"奥赛康,002755,奥赛康股票,奥赛康股票老虎,奥赛康股票老虎国际,奥赛康行情,奥赛康股票行情,奥赛康股价,奥赛康股市,奥赛康股票价格,奥赛康股票交易,奥赛康股票购买,奥赛康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"奥赛康(002755)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供奥赛康(002755)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}